论文部分内容阅读
目的 :研究胃癌及癌前病变患者血清中CEA、CAl9- 9和CAl2 5的水平及其临床意义。方法 :用免疫荧光技术检测 4 0例胃癌患者、35例胃癌术后患者 ,2 0例癌前病变患者和 39例正常人血清中CEA、CAl9- 9和CAl2 5的水平。结果 :胃癌患者血清中CEA、CAl9- 9和CAl2 5的水平分别为 15.2 1土 2 .0 1、51.2 8土 3.2 2和 4 3.2 1土 5.71,阳性率分别为 52 .5%、4 0 %和 6 5% ,联合检测的阳性率为92 .5%。结论 :血清中CEA、CAl9- 9和CAl2 5的检测对胃癌诊断有临床意义 ,联合检测更能提高阳性率 ,且可作为胃癌术后疗效评价和预后判断的指标。
Objective: To study the serum levels of CEA, CAl9-9 and CAl2 5 in patients with gastric cancer and precancerous lesions and their clinical significance. METHODS: The levels of CEA, CAl9-9 and CAl2 5 in serum of 40 patients with gastric cancer, 35 patients with postoperative gastric cancer, 20 patients with precancerous lesions and 39 normal controls were detected by immunofluorescence. Results: The levels of CEA, CAl9-9 and CAl2 5 in serum of gastric cancer patients were 15.2 1 soil 2.01, 51.2 8 soil 3.2 2 and 4 3.2 1 soil 5.71 respectively. The positive rates were 52.5% and 40% respectively. And 65%, the combined positive rate was 92.5%. Conclusion : The detection of CEA, CAl9-9 and CAl2 5 in serum has clinical significance in the diagnosis of gastric cancer. Joint detection can improve the positive rate and it can be used as an indicator for evaluating the efficacy and prognosis of postoperative gastric cancer.